Mindpeak vs Proscia (2026)
Mindpeak sells biomarker scoring algorithms; Proscia sells the platform algorithms run on. Mindpeak lists 11 CE-IVD products for breast and lung biomarkers, reported IVDR certification in September 2026, and has no FDA clearance. Proscia's Concentriq AP-Dx is FDA cleared for primary diagnosis (K230839, K261380), Health Canada licensed and CE marked under the IVDR, and more than 230 applications from Proscia and other makers run on it.
- Biomarker scoring on immunohistochemistry is what you are buying.
- Your laboratory works in Europe, where the products are CE-IVD marked.
- You already run PathAI's AISight, which distributes Mindpeak's algorithms.
- You need a cleared platform for primary diagnosis first.
- You want many makers' applications and more than 45 scanners supported.
- Your security review asks for SOC 2 Type II, ISO 27001 and ISO 13485.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Mindpeak and Proscia are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Mindpeak | Proscia |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2018 | 2014 |
| Headquarters | Hamburg, Germany | Philadelphia, Pennsylvania, United States |
| Website | mindpeak.ai | proscia.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Proscia
-
Regulatory / FDA
Proscia received a new FDA 510(k) clearance for its Concentriq AP-Dx digital pathology platform.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Hamburg based computational pathology company, with a US entity in Cambridge, Massachusetts, focused on biomarker quantification from H&E, immunohistochemistry and multiplex immunofluorescence images. It lists 11 CE-IVD products, covering breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and states that its other products are research use only; it has no FDA clearance.
Source: AI Health Index, September 2026
Digital pathology software company whose Concentriq platform manages, displays and analyzes whole slide pathology images for clinical laboratories and life sciences organizations. Its diagnostic edition, Concentriq AP-Dx, is FDA 510(k) cleared (K230839 in 2024 and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the EU IVDR for primary diagnosis on FFPE surgical pathology slides; the research editions are labeled Research Use Only, a distinction the company draws explicitly.
Source: AI Health Index, September 2026
Questions buyers ask
How do Mindpeak and Proscia work with the EHR?
For Mindpeak, the algorithm reaches the pathologist through someone else's product.
With Proscia, the company states that AI recommended ancillary test requests flow back into the LIS rather than a separate ticket queue, which is a real workflow closure rather than a display feature. The platform also serves as a host environment for third party algorithms, with at least one external spatial biology vendor embedding its predictive biomarker technology into Concentriq. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Mindpeak and Proscia handle patient data?
In Mindpeak's case, the customer must warrant that it owns the necessary rights and has obtained all applicable consents. The upload policy page is marked noindex, so search engines do not surface it.
For Proscia, the platform page states that "everything in Concentriq stays within your organization, unless you give express permission to de-identify and share it to advance research", and that "your data is never used to train the models Concentriq runs". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Mindpeak and Proscia?
With Mindpeak, a study by Abele and colleagues assessed the Breast Ki-67 and ER/PR products for quantifying Ki-67, ER, and PR, finding reliability across a wide range of image variance and pathologist confirmation, and concluding the tools can improve interobserver agreement in real world clinical settings.
In Proscia's case, the earlier dermatopathology classifier was validated across two university hospitals and two commercial dermatopathology laboratories on more than 20,000 biopsy slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Mindpeak and Proscia leave to the clinician?
Mindpeak ships both region of interest products, where the pathologist selects the area analyzed, and whole slide analysis.
With Proscia, the cleared clinical edition is an aid to the pathologist for viewing and interpreting images, and the company's AI applications are for research use only, so no model output reaches a diagnosis without a pathologist. The company's chief executive has publicly argued that the opportunity is removing administrative burden rather than diagnostic expertise, consistent with how the product is scoped. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Mindpeak's general terms grant it a perpetual, sublicensable right to use analyzed images, including to retrain its AI. Proscia's own AI is research use only. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.